BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 11096346)

  • 1. Cellular efflux pump and interaction between cisplatin and paclitaxel in ovarian cancer cells.
    Kamazawa S; Kigawa J; Minagawa Y; Itamochi H; Shimada M; Takahashi M; Sato S; Akeshima R; Terakawa N
    Oncology; 2000 Nov; 59(4):329-35. PubMed ID: 11096346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of docetaxel in paclitaxel-resistant ovarian cancer cells.
    Sato S; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Iba T; Naniwa J; Uegaki K; Terakawa N
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):247-52. PubMed ID: 14610615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer.
    Kamazawa S; Kigawa J; Kanamori Y; Itamochi H; Sato S; Iba T; Terakawa N
    Gynecol Oncol; 2002 Aug; 86(2):171-6. PubMed ID: 12144824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of paclitaxel-induced apoptosis in an ovarian cancer cell line and its paclitaxel-resistant clone.
    Sugimura M; Sagae S; Ishioka S; Nishioka Y; Tsukada K; Kudo R
    Oncology; 2004; 66(1):53-61. PubMed ID: 15031599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves.
    Nishiyama M; Yamamoto W; Park JS; Okamoto R; Hanaoka H; Takano H; Saito N; Matsukawa M; Shirasaka T; Kurihara M
    Clin Cancer Res; 1999 Sep; 5(9):2620-8. PubMed ID: 10499641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin.
    Komuro Y; Udagawa Y; Susumu N; Aoki D; Kubota T; Nozawa S
    Jpn J Cancer Res; 2001 Nov; 92(11):1242-50. PubMed ID: 11714450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered expression of gamma-glutamylcysteine synthetase, metallothionein and topoisomerase I or II during acquisition of drug resistance to cisplatin in human ovarian cancer cells.
    Kikuchi Y; Hirata J; Yamamoto K; Ishii K; Kita T; Kudoh K; Tode T; Nagata I; Taniguchi K; Kuwano M
    Jpn J Cancer Res; 1997 Feb; 88(2):213-7. PubMed ID: 9119751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
    Tanaka T; Masuda H; Naito M; Tamai H
    Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible mechanisms of resistance to cis-diamminedichloroplatinum (II) of human ovarian cancer cells.
    Kikuchi Y; Iwano I; Miyauchi M; Kita T; Sugita M; Tenjin Y; Nagata I
    Jpn J Cancer Res; 1990; 81(6-7):701-6. PubMed ID: 2119370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.
    Nonaka M; Itamochi H; Kawaguchi W; Kudoh A; Sato S; Uegaki K; Naniwa J; Sato S; Shimada M; Oishi T; Terakawa N; Kigawa J; Harada T
    Int J Gynecol Cancer; 2012 Jul; 22(6):922-9. PubMed ID: 22672985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of antiproliferative effect of cis-diamminedichloroplatinum(II) by clomiphene and tamoxifen in human ovarian cancer cells.
    Kikuchi Y; Hirata J; Kita T; Imaizumi E; Tode T; Nagata I
    Gynecol Oncol; 1993 Jun; 49(3):365-72. PubMed ID: 8314539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity to paclitaxel is not related to p53-dependent apoptosis in ovarian cancer cells.
    Takahashi M; Kigawa J; Minagawa Y; Itamochi H; Shimada M; Kamazawa S; Sato S; Akeshima R; Terakawa N
    Eur J Cancer; 2000 Sep; 36(14):1863-8. PubMed ID: 10974635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
    Itamochi H; Kigawa J; Sultana H; Iba T; Akeshima R; Kamazawa S; Kanamori Y; Terakawa N
    Jpn J Cancer Res; 2002 Jun; 93(6):723-8. PubMed ID: 12079522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. cis-Diamminedichloroplatinum-resistant cell lines derived from human epithelial ovarian carcinoma express increased susceptibility to angiogenesis inhibitor TNP-470.
    Tamura M; Takakuwa K; Tanaka K
    Gynecol Oncol; 2004 Feb; 92(2):530-6. PubMed ID: 14766244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin.
    Kobayashi Y; Seino K; Hosonuma S; Ohara T; Itamochi H; Isonishi S; Kita T; Wada H; Kojo S; Kiguchi K
    Gynecol Oncol; 2011 May; 121(2):390-4. PubMed ID: 21272926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of antitumour activity of cisplatin by N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine. HCl in human ovarian cancer cells with intrinsic or acquired resistance to cisplatin.
    Kudoh K; Kikuchi Y; Hiramatsu H; Hirata J; Yamamoto K; Kita T; Nagata I
    Eur J Cancer; 1997 Jan; 33(1):122-8. PubMed ID: 9071911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.
    Minagawa Y; Kigawa J; Itamochi H; Terakawa N
    Hum Cell; 2001 Sep; 14(3):237-43. PubMed ID: 11774743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer.
    Naniwa J; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Shimogai R; Kawaguchi W; Sato S; Terakawa N
    Int J Gynecol Cancer; 2007; 17(1):76-82. PubMed ID: 17291235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.